JP2003529360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003529360A5 JP2003529360A5 JP2001572589A JP2001572589A JP2003529360A5 JP 2003529360 A5 JP2003529360 A5 JP 2003529360A5 JP 2001572589 A JP2001572589 A JP 2001572589A JP 2001572589 A JP2001572589 A JP 2001572589A JP 2003529360 A5 JP2003529360 A5 JP 2003529360A5
- Authority
- JP
- Japan
- Prior art keywords
- nfif
- nfκb
- polypeptide
- nucleic acid
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 13
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 108700008625 Reporter Genes Proteins 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229940122498 Gene expression inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19390500P | 2000-03-31 | 2000-03-31 | |
| US60/193,905 | 2000-03-31 | ||
| GB0018307.9 | 2000-07-26 | ||
| GBGB0018307.9A GB0018307D0 (en) | 2000-07-26 | 2000-07-26 | Polypeptides |
| PCT/US2001/010719 WO2001074900A2 (en) | 2000-03-31 | 2001-04-02 | Nuclear factor kb inducing factor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003529360A JP2003529360A (ja) | 2003-10-07 |
| JP2003529360A5 true JP2003529360A5 (enExample) | 2008-05-15 |
| JP4750999B2 JP4750999B2 (ja) | 2011-08-17 |
Family
ID=26244722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572589A Expired - Fee Related JP4750999B2 (ja) | 2000-03-31 | 2001-04-02 | 核因子κＢ誘導因子 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1290023B1 (enExample) |
| JP (1) | JP4750999B2 (enExample) |
| KR (1) | KR100811571B1 (enExample) |
| AT (1) | ATE486089T1 (enExample) |
| AU (1) | AU4793101A (enExample) |
| CA (1) | CA2404688C (enExample) |
| DE (1) | DE60143354D1 (enExample) |
| DK (1) | DK1290023T3 (enExample) |
| IL (3) | IL151987A0 (enExample) |
| MX (1) | MXPA02009481A (enExample) |
| NO (1) | NO331972B1 (enExample) |
| NZ (1) | NZ521786A (enExample) |
| PT (1) | PT1290023E (enExample) |
| WO (1) | WO2001074900A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117534753B (zh) * | 2023-12-07 | 2024-05-10 | 北京博奥森生物技术有限公司 | 一种诱导高性能NF-κB多克隆抗体多肽及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3486053T3 (de) | 1983-10-20 | 2004-01-08 | The Research Foundation Of State University Of New York | Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS. |
| FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| WO1992015680A1 (en) | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
| WO1993008845A1 (en) | 1991-11-08 | 1993-05-13 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| EP0651805B1 (en) | 1992-07-17 | 2006-12-13 | Dana Farber Cancer Institute | Method of intracellular binding of target molecules |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| FR2706486B1 (fr) | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| WO1997037020A1 (en) * | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
| US6235512B1 (en) * | 1997-07-01 | 2001-05-22 | Tularik Inc. | IKK-α proteins, nucleic acids and methods |
| US6132964A (en) * | 1998-02-06 | 2000-10-17 | Incyte Pharmaceuticals, Inc. | Hydrolase enzymes |
| AU4187499A (en) * | 1998-05-14 | 1999-11-29 | Chiron Corporation | Human genes and gene expression products v |
| GB9814036D0 (en) * | 1998-06-29 | 1998-08-26 | Univ Dundee | Materials and methods relating to the induction of apoptosis in target cells |
| US6077672A (en) * | 1998-08-28 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of TRADD expression |
| CN1302897A (zh) * | 1999-10-28 | 2001-07-11 | 上海博容基因开发有限公司 | 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸 |
| CA2402563A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| EP1358347A2 (en) * | 2000-04-05 | 2003-11-05 | Incyte Genomics, Inc. | Genes expressed in foam cell differentiation |
| EP1358349A2 (en) * | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
-
2001
- 2001-04-02 JP JP2001572589A patent/JP4750999B2/ja not_active Expired - Fee Related
- 2001-04-02 DK DK01920925.3T patent/DK1290023T3/da active
- 2001-04-02 EP EP01920925A patent/EP1290023B1/en not_active Expired - Lifetime
- 2001-04-02 AT AT01920925T patent/ATE486089T1/de active
- 2001-04-02 PT PT01920925T patent/PT1290023E/pt unknown
- 2001-04-02 MX MXPA02009481A patent/MXPA02009481A/es active IP Right Grant
- 2001-04-02 IL IL15198701A patent/IL151987A0/xx unknown
- 2001-04-02 AU AU4793101A patent/AU4793101A/xx not_active Withdrawn
- 2001-04-02 WO PCT/US2001/010719 patent/WO2001074900A2/en not_active Ceased
- 2001-04-02 CA CA2404688A patent/CA2404688C/en not_active Expired - Fee Related
- 2001-04-02 DE DE60143354T patent/DE60143354D1/de not_active Expired - Lifetime
- 2001-04-02 KR KR1020027013083A patent/KR100811571B1/ko not_active Expired - Fee Related
- 2001-04-02 NZ NZ521786A patent/NZ521786A/en not_active IP Right Cessation
-
2002
- 2002-09-27 NO NO20024656A patent/NO331972B1/no not_active IP Right Cessation
- 2002-09-29 IL IL151987A patent/IL151987A/en not_active IP Right Cessation
-
2009
- 2009-04-16 IL IL198132A patent/IL198132A0/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant | |
| Glass et al. | Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice | |
| Brasier et al. | Nuclear heat shock response and novel nuclear domain 10 reorganization in respiratory syncytial virus-infected a549 cells identified by high-resolution two-dimensional gel electrophoresis | |
| JP2007506426A5 (enExample) | ||
| CA2363486A1 (en) | Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol | |
| JP2002540127A5 (enExample) | ||
| JP2008526876A5 (enExample) | ||
| Black et al. | Effect of vesicular stomatitis virus matrix protein on host-directed translation in vivo | |
| JP2006518186A5 (enExample) | ||
| JP2006512292A5 (enExample) | ||
| US5821339A (en) | Compositions and methods for treatment of herpesvirus infections | |
| JP2002512005A5 (enExample) | ||
| JP2003529360A5 (enExample) | ||
| JP2004535795A5 (enExample) | ||
| JP2005535289A5 (enExample) | ||
| JP2006503575A5 (enExample) | ||
| WO2007064844A3 (en) | Anti-viral griffithsin compounds, compositions, and methods of use | |
| JP2004535161A5 (enExample) | ||
| WO2002022661A3 (en) | NOVEL PDEs AND USES THEREOF | |
| US9125861B2 (en) | PAR2 agonists for use in the treatment or prevention of influenza virus type A infections | |
| Shetzline et al. | Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome | |
| Mühlemann et al. | Enhanced splicing of nonconsensus 3'splice sites late during adenovirus infection | |
| JP2005516604A5 (enExample) | ||
| CA2315976A1 (en) | Serine protease inhibitors | |
| JP2003113111A5 (enExample) |